Search results
Results from the WOW.Com Content Network
Choroideremia (/ k ɒ ˌ r ɔɪ d ɪ ˈ r iː m i ə /; CHM) is a rare, X-linked recessive form of hereditary retinal degeneration that affects roughly 1 in 50,000 males. The disease causes a gradual loss of vision, starting with childhood night blindness, followed by peripheral vision loss and progressing to loss of central vision later in life.
Choroideremia-deafness-obesity syndrome This condition is inherited in an X-linked recessive manner. Ayazi syndrome (or Chromosome 21 Xq21 deletion syndrome ) [ 1 ] is a syndrome characterized by choroideremia , congenital deafness and obesity .
Some of the most common signs and symptoms of low testosterone in men include: Reduced drive. ED. Testicular shrinkage. ... But it may also cause side effects like skin irritation (particularly ...
Long-term use of such medications must be closely monitored, however, due to the discomforting and potentially debilitating and life-threatening side-effects. [ 11 ] [ 12 ] Immunosuppressive drugs such as the therapeutic monoclonal antibody daclizumab , ciclosporin , methotrexate and Adalimumab , sold under the trade name Humira, have proven to ...
Complications may adversely affect the prognosis, or outcome, of a disease. Complications generally involve a worsening in the severity of the disease or the development of new signs, symptoms, or pathological changes that may become widespread throughout the body and affect other organ systems. Thus, complications may lead to the development ...
These adverse sexual side effects are typically seen in less than 5% of men on the drug. There is also a link to mental health effects, including depression. However, it’s unclear how common ...
And then there are those who suffered an unexpected setback such as a cancer diagnosis, a job loss, or a divorce and wish they'd been better prepared for an emergency. We want to hear from you.
These side effects may occur in as many as 90% of men treated with bicalutamide monotherapy, [29] but gynecomastia is generally reported to occur in 70 to 80% of patients. [30] In the EPC trial, at a median follow-up of 7.4 years, breast pain and gynecomastia respectively occurred in 73.6% and 68.8% of men treated with 150 mg/day bicalutamide ...